Streetbeat News

Analyst Ratings

NAMS

RBC Capital analyst Leonid Timashev has reiterated an Outperform rating for NewAmsterdam Pharma (NASDAQ:NAMS) and maintained a price target of $31.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 4:00 pm

CNC

Centene (NYSE:CNC) has received 17 analyst ratings over the past three months, with a mix of bullish and bearish perspectives. The average 12-month price target is $88.18, slightly down from the previous $90.18. Analysts have adjusted their ratings and price targets based on market conditions and company performance. Centene's financial performance shows a revenue growth of 5.92%, a net margin of 2.88%, and a high debt-to-equity ratio of 0.64.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:00 pm

STWD

Analysts have provided mixed ratings for Starwood Property Trust (NYSE:STWD), with a recent increase in the average 12-month price target to $21.5. Despite a negative revenue trend, the company shows strong profitability and financial health.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:00 pm

BIDU

Analysts have varied opinions on Baidu (NASDAQ:BIDU), with recent ratings showing a shift towards more conservative price targets. The average 12-month price target has decreased by 13.05% to $123.9. Despite a decline in revenue growth, Baidu maintains strong profitability metrics, including a net margin of 16.17% and a debt-to-equity ratio of 0.33.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:00 pm

BAH

Booz Allen Hamilton (NYSE:BAH) has been analyzed by six analysts, showing a range of sentiments from bullish to bearish. The average 12-month price target is $155.17, with a high of $165.00 and a low of $140.00. Analysts have decreased the average price target by 1.17%. The company shows strong financial health with a 10.82% revenue growth rate, a net margin of 5.59%, and a return on equity of 15.44%. However, its debt-to-equity ratio is higher than the industry average, indicating higher financial risk.

Portfolio Pulse from Benzinga Insights

September 05, 2024 | 4:00 pm

APTV

RBC Capital analyst Tom Narayan maintains an Outperform rating on Aptiv (NYSE:APTV) and raises the price target from $85 to $87.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 3:58 pm

LZ

JP Morgan analyst Ella Smith maintains a Neutral rating on LegalZoom.com (NASDAQ:LZ) and lowers the price target from $9 to $8.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 3:57 pm

BMRN

RBC Capital analyst Luca Issi has reiterated a Sector Perform rating for Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $100.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 3:56 pm

CELH

Jefferies analyst Kaumil Gajrawala maintains a Buy rating on Celsius Holdings (NASDAQ:CELH) but lowers the price target from $68 to $53.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 3:54 pm

CARR

RBC Capital has maintained its 'Outperform' rating on Carrier Global and raised the price target from $72 to $79, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 05, 2024 | 3:52 pm